

# **Study of Kappa to Lambda ratio in Multiple Myeloma as a predictor of outcome and prognostic factor in Egyptian patients**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree  
in Clinical Hematology*

by

**Ibrahim Abd EL-Hak EL-Saied**

M.B.B.Ch

**Supervised By**

**Prof. Dr. Mohamed Osman Azzazi**

*Professor of Internal Medicine and Clinical Haematology  
Faculty of Medicine , Ain Shams University*

**Prof. Dr. Mohamed Mahmoud Moussa**

*Professor of Internal Medicine and Clinical Haematology  
Faculty of Medicine , Ain Shams University*

**Prof. Dr. Hany Mohamed Hegab**

*Professor of Internal Medicine and Clinical Haematology  
Faculty of Medicine , Ain Shams University*

**Faculty of Medicine  
Ain Shams University  
2018**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قالوا

لَسْبَدَّانِكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First of all and above all great thanks to **ALLAH** whose blessings on me cannot be counted.*

*The sincerest thanks, deepest appreciation and greatest admiration to my **Prof. Dr. Mohamed Osman Azzazi** Professor of Internal Medicine & Clinical Hematology, Faculty of Medicine, Ain Shams University, for his constructive keen supervision, Fruitful criticism, continuous support and encouragement to complete this work. I really have the honor to complete this work under his supervision.*

*I feel greatly indebted to **Prof. Dr. Mohamed Moussa**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine- Ain Shams University, for his trustful help, sincere guidance, continuous support and assistance.*

*Finally, I would like to thank **Prof. Dr Hany Mohamed Hegab** Professor of Internal Medicine and Hematology, Faculty of Medicine- Ain Shams University, for the efforts and time he has devoted to accomplish this work.*

*Last but not least, I can't forget to thank all members of my Family, specially **my wife and my Parents**, for their support and care. Candidate*

*Ibrahim Abd El-Hak El-saied*

# **List of Contents**

List of Abbreviations.....	i
List of Tables.....	iv
List of Figures.....	vi
<b>Introduction.....</b>	<b>1</b>
<b>Aim of the Work.....</b>	<b>9</b>
<b>Review of Literature</b>	
Historical perspective .....	10
criteria for diagnosis and staging.....	11
Role of the serum FLC assay .....	30
Patients and Methods.....	44
Results .....	56
Discussion .....	76
Summary.....	87
Conclusion .....	90
Recommendations.....	91
References .....	92
Arabic    Summary.....	

---

---

## List of Abbreviations

---

Abbreviations	Full term
AKI	: Acute kidney injury
AL	: Amyloidosis
BMT	: Autologous bone marrow transplantation
BJP	: Bence Jones protein
CG	: Cytogenetic
CR	: Complete response
CT	: Computerized tomography
DM	: Diabetes mellitus
FISH	: Florescence in situ hybridization
FLCs	: Free light chains
HB	: Hemoglobin
IF	: Immunofixation
IgA	: Immunoglobulin A
IgD	: Immunoglobulin D
IgE	: Immunoglobulin E
IgG	: Immunoglobulin G
IgM	: Immunoglobulin M
IHD	: Ischemic heart disease
IMWG	: International Myeloma Working Group
ISS	: International staging system

---

## List of Abbreviations (Cont.)

---

Abbreviations	Full term
LCDD	: Light chain deposition disease
LCMM	: Light chain multiple myeloma
MGUS	: Monoclonal gammopathy of undetermined significance
MM	: Multiple myeloma
MRI	: Magnetic resonant imaging
NCCN	: National Comprehensive Cancer Network
NSMM	: Non-secretory myeloma
PCR	: Polymerase chain reaction
PD	: Progressive disease
Plt	: Platelet
POEMS	: Osteosclerotic myeloma
PR	: Partial response
S.Ca	: Serum calcium
sCR	: Stringent complete response
SD	: Stable disease
SIFE	: Serum immunofixation electrophoresis
SMM	: Smoldering multiple myeloma
SPEP	: Serum protein electrophoresis
TLC	: Total light chains

---

## List of Abbreviations (Cont.)

---

Abbreviations	Full term
UIFE	: Urine immunofixation electrophoresis
UPEP	: Urine protein electrophoresis
VCD	: Velcade, cyclophosphamide, dexamethasone
VGP R	: Very good partial response
VTD	: Velcade, thalidomide, dexamethasone
WM	: Waldenström's macroglobulinaemia
β2	: Beta-2
κ/λ FLC ratio	: Kappa : Lambda free light chain ratio

## List of Tables

<b>Table</b>	<b>Title</b>	<b>Page</b>
1	Half-life of immunoglobulin's	24
2	International staging system & R- International staging system	26
3	Mayo risk stratification for myeloma definition of high risk	28
4	IMWG uniform response criteria for multiple myeloma	29
5	Adult serum range of K:L FLCs ratio expected test value	53
6	Adult urine range of K:L FLCs ratio expected test value	54
7	Demographic data distribution of the study group	56
8	CBC distribution of the study group	56
9	Kidney function descriptive of the study group	57
10	S.Ca total and S.Ca ionized descriptive of the study group	57
11	Diagnostic test for multiple myeloma descriptive of the study group	58
12	Disease status post induction, auto BMT (after 1 <sup>st</sup> line) and auto BMT distribution of the study group	61
13	Relation between sex and age (years)	62
14	Relation between K:L ratio and all parameters	63-64
15	Relation between Cytogenetics with immunofixation and SPEP	66
16	Relation between disease status post induction and age, sex, diagnostic test for MM	67



## **List of Tables (Cont.)**

<b><i>Table</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
17	Relation between Auto BMT and diagnostic test for MM	70
18	Correlation between plasma cell % in bone marrow and Hb,B2 (mg/L), K:L ratio	72
19	Relation between osteolytic lesions with S.ca total, S.ca ionized, diagnostic test for multiple myeloma	74

## List of Figures

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
1	<b>a-b</b> microscopic picture of plasma cell (a) and stages of plasma cell proliferation (b)	2
2	heavy and light	5
3	osteolytic lesion at distal end of femur	12
4	M band shape	22
5	pattern of biclonal gammopathy	22
6	IgG Kappa and Lambda Light chain	23
7	Dotplot of sFLC concentrations in patients with monoclonal gammopathies	40
8	Freelite	46
9	Pie chart immunofixation distribution of the study group.	59
10	Pie chart B2 (mg/l) distribution of the study group	59
11	Pie chart cytogenetics distribution of the study group	60
12	Pie chart disease status post induction distribution of the study group	62
13	Bar chart relation between sex and age (years)	62
14	Bar chart between K:L ratio and all parameters	65
15	Bar chart relation between cytogenetics with immunofixation	66
16	Bar chart between disease status post induction and immunofixation	68
17	Bar chart between disease status post induction and B2	68
18	Bar chart between disease status post induction and cytogenetics	69

## List of Figures (Cont.)

<b><i>Fig.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
19	Bar chart between disease status post induction and K:L ratio	69
20	Bar chart between Auto BMT and cytogenitics	71
21	Scatter plot between plasma cell% in bone marrow and Hb	72
22	Scatter plot between plasma cell% in bone marrow and K:L ratio	73
23	Bar chart relation between osteolytic lesions and cytogenitics	75


# Introduction

Multiple myeloma (MM) is heterogeneous malignant neoplasm that occurs mainly in patients over 50 years of age characterized by neoplastic proliferation of a single clone of plasma cells (fig 1 a - b) producing a monoclonal immunoglobulin. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures. (*Kyle RA, et al. 2004*)

The diagnosis of multiple myeloma is often suspected because of one or more of some clinical presentations as; bone pain with lytic lesions discovered on routine skeletal films, an increased total serum protein concentration and/or the presence of a monoclonal protein in the urine or serum, systemic signs or symptoms suggestive of malignancy, such as unexplained anemia, hypercalcemia, which is either symptomatic or discovered incidentally, is common, acute renal failure with a bland urine analysis or rarely the nephrotic syndrome due to concurrent primary amyloidosis. (*Kariyawasan et al., 2007*)

It is important to distinguish multiple myeloma both from other causes of the clinical presentations above and other plasma cell dyscrasias for the purposes of prognosis and treatment. It is also important to evaluate patients suspected of having multiple myeloma in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course.

Most patients with MM present with signs or symptoms related to the infiltration of plasma cells into the bone marrow, kidney damage or other organs from excess light chains. (*Kariyawasan et al., 2007*)



**Fig. (1:a-b)** microscopic picture of plasma cell (a) and stages of plasma cell proliferation (b) ) (*Kyle RA et al. 2004*)

---

## EPIDEMIOLOGY

MM accounts for approximately 1 percent of all cancers and slightly more than 10 percent of hematologic malignancies in the United States (US). The annual incidence in the US is approximately 4 to 5 per 100,000. A similar incidence has been reported in the South Thames area of the United Kingdom and in European general. (*Kyle. RA, et al., 2004*) The median age at diagnosis is 66 years.

MM occurs in all races and all geographic locations. The incidence varies by ethnicity; the incidence in African Americans and blacks from Africa is two to three times that in whites (*Huang SY, et al., 2007*)

A small but unknown fraction of cases are familial. The risk of developing MM is approximately 3.7-fold higher for persons with a first-degree relative with MM. MM has been reported in clusters of two or more first-degree. (*Lynch. HT, et al., 2001*)

In Egypt the data are limited to determine the actual incidence rate but there is study done To determine the clinical and laboratory characteristics and survival of diagnosed Egyptian multiple myeloma patients admitted to

the Haemato-Oncology Department between 2000 and 2010. Records of all patients in whom multiple myeloma was diagnosed at the Kasr Al Aini Hospital between 2000 and 2010 were included in this retrospective study. The mean age of patients was 58.5 years (range, 27-80 years). Fifty-nine percent were males. The majority of patients (73 %) had an immunoglobulin G monoclonal band and 70 % were Kappa chain-positive. Mean overall survival was 37.5 months (range, 1-84 months). *El Husseiny N, et al (2013)*

Survival analysis was statistically insignificant with respect to age, sex, International Staging System and type of treatment ( $p > 0.05$ ). Our records were largely comparable to those reported in Chinese studies but different from those noted in Western and Arabic countries. (*Qiu L, et al., 2008*).

Detection of monoclonal free light chains (FLCs) (fig 2) is important for diagnosis and monitoring of monoclonal gammopathies. Although FLCs are especially important in light-chain diseases, such as light-chain myeloma, primary systemic (AL) amyloidosis, and light-chain deposition disease, FLC abnormalities occur in as many as 97% of plasma cell disorders, including 95% of